Skip to main content

Drug Interactions between Adstiladrin and Imfinzi

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

durvalumab nadofaragene firadenovec

Applies to: Imfinzi (durvalumab) and Adstiladrin (nadofaragene firadenovec)

GENERALLY AVOID: The administration of live, attenuated viral or bacterial vaccines during treatment with immune checkpoint inhibitors (ICI) such as programmed cell death-1 (PD-1), programmed death ligand-1 inhibitors (PD-L1), and anti-CTLA-4 monoclonal antibodies may theoretically be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. These patients may also have decreased or suboptimal immunologic response to vaccines or oncolytic immunotherapy. Data evaluating the impact of these drugs on the safety and effectiveness of these vaccines or oncolytic immunotherapy agents are not available.

MANAGEMENT: Until more information is available, coadministration of live, attenuated or bacterial vaccines or oncolytic cancer immunotherapy agents with immune checkpoint inhibitors (ICI) should generally be avoided. Product labeling for certain ICIs such as atezolizumab, dostarlimab, and durvalumab specify that patients who received live vaccines were excluded from clinical trials whereas other ICI product labels provide no specific information or guidance. Guidelines on the use of vaccines in adults with cancer by the American Society of Clinical Oncology (ASCO) recommends patients receive live vaccines 2-4 weeks before cancer treatment. The U.S. Centers for Disease Control and Prevention (CDC) advise that, due to limited research on vaccination following immunotherapy with ICIs, live attenuated vaccines should be avoided for patients receiving these treatments for 3-6 months post-treatment, or until immune recovery is confirmed. Local guidelines and individual product labeling for the live vaccine and the ICI being used should be consulted for more specific recommendations.

References

  1. (2023) "Product Information. Jemperli (dostarlimab)." GlaxoSmithKline, SUPPL-6
  2. (2023) "Product Information. Tecentriq (atezolizumab)." Genentech, SUPPL-51
  3. (2023) "Product Information. Imfinzi (durvalumab)." Astra-Zeneca Pharmaceuticals, SUPPL-42
  4. (2024) "Product Information. Tecentriq Hybreza (atezolizumab-hyaluronidase)." Genentech
  5. Kamboj M, Bohlke K, Baptiste DM, et al. (2024) Vaccination of adults with cancer: ASCO guideline https://ascopubs.org/doi/pdf/10.1200/JCO.24.00032#xd_co_f=MWFjNGQ0MzctYjA5OS00NWM1LThlZDktZDBiNzIxMWZiYTk1~
  6. Kotton C, Kroger A, Freedman D (2024) Immunocompromised travelers. In CDC Yellow Book 2024: Health information for international travel. https://wwwnc.cdc.gov/travel/yellowbook/2024/additional-considerations/immunocompromised-travelers
View all 6 references

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.